Ready for a close-up because… The agency’s addition of a market access offering — and with it, work in that sector for Ipsen, among others — gave it a professional calling card that few firms of its size can match. At the same time, CrowdPharm rose to meet the year’s overarching challenge with work on FluroTest’s COVID-19 antigen testing platform. In doing so, it distinguished itself in a sector populated predominantly by firms many times its size.
Thank you for accessing MM+M.
Create your free account or log in to continue reading this premium content.